Nephron [creativecommons license] via Wikimedia Commons
Hepatocellular carcinoma (HCC), the most common type of liver cancer in the US, is often treated by removing the tumor. But relapse after resection is very common, and there are currently no effective therapies for reducing recurrence. Approaches that activate a patient’s immune system to fight cancer recurrence have been tested but so far have induced only weak responses. Now, Yukai He (Medical College of Georgia, Augusta) and colleagues have found a way to boost the efficacy of immune stimulation against liver cancer.
Lab Anim. (NY) 43, 257 (2014).
view full text (login required)